Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Health dept data shows 1.93m reported cases of respiratory disease in 30 days; complaints of asthma, conjunctivitis, heart ...

The prescribing of antiviral drugs for US children and adolescents receiving treatment for influenza was less than 60% in the ...

Scientists have developed a new technology to efficiently isolate a specific subset of gut bacteria from fecal samples that are recognized by IgA antibodies. These 'IgA-coated' bacteria are associated ...

The announcement represents the Commission's formal recognition of ground cannabis dust as a hazardous chemical that can ...

People living with HIV may also have to manage other health conditions like cardiovascular disease, type 2 diabetes, ...

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

A rehabilitation centre for women in Shediac, N.B. is trying to expand its services, but it's getting pushback from residents ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.